ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Recruiting

Phase 2

ATI-045ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Sponsor:

Aclaris Therapeutics, Inc.

Code:

NCT07011706

Conditions

Atopic Dermatitis

Atopic

Dermatitis

Eczema

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

ATI-045

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-21. This information was provided to ClinicalTrials.gov by Aclaris Therapeutics, Inc. on 2026-01-13.